ValiRx and Omios Biologics Collaborate on Oncolytic Cancer Therapies

The latest announcement is out from ValiRx plc ( (GB:VAL) ).

ValiRx plc, through its subsidiary Cytolytix Ltd., has entered into an Evaluation and Material Transfer Agreement with Omios Biologics to assess the potential of Cytolytix’s CLX001 oncolytic peptide technology in enhancing Omios’s next-generation oncolytic virus immunotherapies. This collaboration represents a strategic opportunity for ValiRx to expand its portfolio and commercialize innovative cancer therapeutics, potentially leading to a licensing agreement. The partnership aligns with Omios’s strategy to advance transformative cancer treatments, offering significant implications for both companies in the field of oncolytic immunotherapy.

More about ValiRx plc

ValiRx is a life sciences company that focuses on early-stage cancer therapeutics and women’s health. The company accelerates the translation of innovative science into impactful medicines to improve patient lives, providing a framework for rapid clinical development. ValiRx is listed on the AIM Market of the London Stock Exchange and collaborates with various partners to streamline drug development processes.

Average Trading Volume: 1,687,585

Technical Sentiment Signal: Sell

Current Market Cap: £2.06M

For detailed information about VAL stock, go to TipRanks’ Stock Analysis page.